ZINC CATION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Zn
Molecular Weight	65.409
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[Zn++]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N

InChI=1S/Zn/q+2

HIDE SMILES / InChI

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6309044

Zinc fluoride (ZnF2) is used in the fluorination of organic compounds, in the manufacturing of phosphors for fluorescent lights, in preserving wood, in electroplating baths, in galvanising steel, and making ceramics. It is also used as a termite repellent, in medication, and in glazes and enamels for porcelain. Zn compounds have been used as active ingredients in dentifrice for anti-calculus, antimicrobial/gingivitis, and anti-malodor for a long time. ZnF2/HCl might have potential benefit as a staining-free agent to tooth substrate for root caries prevention. It has being shown to have antiplaque and caries preventive effects. Zinc fluoride protects enamel, dentine and the root area against caries.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 8146
respiratory burst 39 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1404
transformed cell apoptotic process 106 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1404
Methotrexate 38 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 38
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 314
T cell mediated immunity 40 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1404
Zinc transporter ZIP1 38 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1037
Zinc transporter ZIP2 38 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1037

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2554
Unknown 2554
Unknown 2554
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 122 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8307	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date -4.55328006E11
Zinc deficiency 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8307	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 1.32675836E12
Diaper dermatitis 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8307	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 1.140048E12
Poison Ivy dermatitis 38 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8307	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 94 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8307	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Mucositis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Dysgeusia 38 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Unknown 2554

PubMed

Title	Date	PubMed
In vitro activity of zinc salts against human rhinoviruses.	1987 Apr	3038000
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.	1991 Apr 1	9996367
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.	1991 Sep 10	1888732
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.	1993 Aug	8404763
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.	1994 Dec	7899834
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.	1997 Feb	9021177
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.	2006 Dec	17093223
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.	2007 May	17301066
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.	2007 Nov	18055849
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.	2009 Mar 28	19382294
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.	2010 Dec	20729176
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.	2010 Dec 1	20851137
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.	2010 Dec 15	20934491
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.	2010 Jan 12	19897006
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.	2010 Jul	20194077
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.	2010 Oct	20708676
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.	2011 Dec	21903158
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.	2011 Mar 21	21341804
Responses of human cells to ZnO nanoparticles: a gene transcription study.	2011 Nov	21769377
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.	2011 Nov 30	21974847
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.	2011 Sep	21642632
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.	2012 Apr	22240982
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.	2012 Feb	22112499
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.	2012 Feb	21964423
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.	2012 Jun 25	22640810
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.	2012 Mar	22166487
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.	2012 Mar	22137962
Glucarpidase for the treatment of life-threatening methotrexate overdose.	2012 Nov	23170306
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.	2013 Dec	23519475
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.	2013 Jul 31	23726862
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.	2013 Mar	23232460
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.	2013 Sep	23352990
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.	2014 Apr	24368203
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.	2014 Jul 1	24746987
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.	2014 Mar 3	24374571
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.	2014 May 15	24780487
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.	2014 May 16	24631018
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.	2014 May 16	24614525
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.	2014 Nov 4	25127755
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.	2015 Apr 2	25680694
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.	2015 Sep	25631103

Patents

Sample Use Guides

In Vivo Use Guide

single intravenous injection of 50 Units per kg

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 16 18:03:37 UTC 2022` Edited by `admin` on `Fri Dec 16 18:03:37 UTC 2022`
Record UNII	13S1S8SF37
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC CATION

Common Name

English

ZINC ION

Common Name

English

ZINC(II)

Systematic Name

English

ZINC ION(2+)

Common Name

English

ZINC(2+)

Systematic Name

English

ZINC, ION (ZN2+)

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175530